Posts Tagged ‘drug discovery’

A Glimpse at Drug Discovery’s Future from H3 Biomedicine CEO Markus Warmuth

October 5th, 2012
Posted by

As many of you know, R&D progress in drug discovery has been a challenge for “big pharma” and biotech firms alike. The costs and risks are enormous, and the rewards are increasingly elusive. For many young firms, the “valley of death” is a very real obstacle as cash burn rates exceed the pace of successful delivery of new drugs to market. What can startups (and larger companies) do? Markus Warmuth, CEO of Cambridge, Massachusetts-based H3 Biomedicine, talked with us about his company’s strategies for giving drug discovery a much-needed boost.
H3 Biomedicine Inc. is a privately held, uniquely structured oncology discovery enterprise. H3 is applying the expertise of leading scientists to the integration of insights from cancer genomics with innovative capabilities in synthetic chemistry and tumor biology to discover patient-based, genomics-driven, small molecule drugs, which represent the most promising current opportunity in cancer therapeutics. H3 Biomedicine will achieve its goals through a unique relationship with the pharmaceutical company Eisai Inc. Eisai has pledged up to $200 million in research funding to H3 Biomedicine, as well as additional support for the clinical development of H3 Biomedicine programs.
  Read the rest of this entry »

Tags: , , , , , ,
Posted in Our Views | Comments Off on A Glimpse at Drug Discovery’s Future from H3 Biomedicine CEO Markus Warmuth

Through the Murky Slog: Part II—A New Light for Cancer Therapies?

November 9th, 2011
Posted by

Last week, we discussed new drug approvals that reflected a paradigm shift for cancer drug development and for treatment of people living with cancer. Finally, we are starting to see a matchup of specific diagnostics with targeted biotherapeutics to address (effectively, we hope) targeted treatments for smaller groups of cancer patients.
Just recently, the American Society for Clinical Oncology (ASCO) urged the use of new biological knowledge to develop treatments faster, design more targeted clinical trials, and use information technology to integrate once-separate translational and clinical research. ASCO even says that targeted therapies can improve clinical trial responses from 8 to 30 percent. Also, just recently, the FDA gave itself a pat on the back as it highlighted its recent innovative drug approvals, with targeted cancer therapies included among those on the list.
  Read the rest of this entry »

Tags: , , , , ,
Posted in Our Views | 1 Comment »

Are We at the End of a Long, Murky Slog in Cancer Treatment?

November 4th, 2011
Posted by

For many years, a lot of people (including us) have called for a new way to look at, diagnose, and treat cancer. This means changing everything – from how we classify cancer to research strategies to treatment regimens. It’s been a long slog, through murky data and lots of failures, but now we’re finally seeing targeted treatments, matched with diagnoses to select the right niche of patients. Best of all, there is strong evidence to suggest that those treatments may work very well in those patient cohorts.
These are unlike most current cancer therapies, which are marked by “broad brush” descriptions (“a breast cancer drug”) and expensive price tags that can wipe out savings, burden insurance companies, and may have little benefit. But the FDA has just approved a series of treatments (albeit for rarer and later-stage cancers) that come with companion diagnostics to make sure the patient is the right one (i.e., has the right biomarker profile) for that drug. Identification of these patients prior to treatment means that while the treatments are still very costly, they stand a much better chance of actually working.
Just recently, the FDA approved (under its fast-track NDA approval system):
  Read the rest of this entry »

Tags: , , , , , , , ,
Posted in Our Views | Comments Off on Are We at the End of a Long, Murky Slog in Cancer Treatment?

Moving Beyond The Whack-a-Mole Style of Cancer Treatment

September 26th, 2011
Posted by

In his latest Wall Street Journal column (“Drugs That Are as Smart as Our Diseases”), biologist/author Matt Ridley bemoans the plummeting efficiency of drug discovery in the pharmaceutical industry. He points to a disturbing paradox: while identifying and sequencing genes of pathogens and cancer cells has become much cheaper in a short period of time, the number of new drug candidates (based at least in part on our knowledge of those genes) has dropped. According to Ridley, new molecule approvals per billions of dollars of inflation-adjusted R&D amounts to no more than one percent of the number of approvals in 1950. And as we’re all aware, this decline in innovation is all the more dire because the pharmaceutical industry needs to replace so-called “blockbuster” drugs that are about to lose their patent protections if it is to continue to keep investors satisfied and fuel future innovation.
So, why hasn’t the same industry that gave us statins, Herceptin®, and vaccines come up with a new generation of treatments? The biggest problem might lie in its success. Researchers today confront an enormous—and growing—amount of genetic and biochemical information as the search continues for newer, more effective drugs.  As we generate more data, we are increasing our understanding of the complexity of biological processes underlying disease states.  While this better understanding can lead to innovation, it also has uncovered obstacles. For example, scientists have found that signaling pathways leading to cancers are replete with redundancy, shortcuts and other molecular detours that block the activity of cancer drugs. Sometimes, these pathways can help eliminate or prevent cancer; at other times they can exacerbate it.
  Read the rest of this entry »

Tags: , , , , , ,
Posted in Our Views | Comments Off on Moving Beyond The Whack-a-Mole Style of Cancer Treatment

TRI-CON – Diagnostics, Drug Discovery & Biologics: Oh My!

February 21st, 2011
Posted by

Sometimes, between the hotel room, the lectures, the networking, the power lunches and the data consumption at a conference, you’re on the plane home before you have time to reflect upon why you attended in the first place. I’m excited to be heading to the 18th International Molecular Medicine Tri-Conference in San Francisco this week—and I’m setting out my reasons for going this year beforehand.
I always look forward to this conference because of its balanced range of life science topics, including those with technical, scientific, business, strategy, regulatory and reimbursement slants. Within this balanced range of topics, the Tri-Con uses a channel structure to help attendees “tune in” where they can get the biggest bang for their buck. I’m excited to learn more about the following specifics within each channel: Read the rest of this entry »

Tags: , , , , , , , , , , ,
Posted in Our News | Comments Off on TRI-CON – Diagnostics, Drug Discovery & Biologics: Oh My!